Embarkneuro
EmbarkNeuro is a neuroscience-focused biotech portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. EmbarkNeuro has a Phase II asset being evaluated in patients with major depressive disorder. The company was formed following the in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co, Ltd. At EmbarkNeuro, we are: patient-centric, collaborative, curious and courageous.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
5
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Embarkneuro
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Embarkneuro
1 distinct titles indexed · top 1 shown.
- 1vice president clinical operations
Sign up to unlock all 1 contacts at Embarkneuro
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Embarkneuro
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.